Maravai LifeSciences (NASDAQ:MRVI), Inc. is a biotechnology company specializing in providing critical reagents, assays and services that support the development and manufacture of vaccines, gene therapies and other biologics. The company’s product portfolio spans nucleic acid labeling technologies, lipid nanoparticle components for mRNA delivery, high-purity plasmid DNA and protein analysis reagents. Through its cGMP-compliant manufacturing capabilities, Maravai enables clients ranging from academic researchers to leading biopharmaceutical firms to accelerate programs from early discovery through commercial scale production.
Founded through a series of strategic acquisitions, Maravai has integrated expertise from TriLink Biotechnologies, Cygnus Technologies, SurModics and Aldevron to build a unified platform for life-science innovation. These transactions have broadened the company’s offerings to include next-generation sequencing sample preparation, LNP formulation for mRNA vaccines, vsdetection systems for nucleic acids and proteins, and custom plasmid and protein manufacturing under stringent regulatory standards. This approach has allowed Maravai to maintain a diversified business model that addresses both research and commercial manufacturing needs.
Headquartered in San Diego, California, Maravai LifeSciences operates manufacturing and research facilities across North America, Europe and Asia. The company’s global footprint ensures timely supply chain support and regulatory alignment for biologics programs around the world. By upholding rigorous quality controls and leveraging a network of technical service teams, Maravai helps clients navigate complex regulatory requirements and optimize process development timelines.
Under the leadership of President and Chief Executive Officer Bradley Thompson, Maravai continues to invest in innovation and capacity expansion. The executive team combines deep experience in biologics, vaccine development and commercial operations, guiding the company’s mission to accelerate breakthroughs in public health and therapeutic research. Maravai’s integrated platform and commitment to quality position it as a key partner for organizations advancing next-generation medicines and vaccines.
